These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 12151478)
1. Comparison of angioplasty with stenting in acute myocardial infarction. Herrmann HC N Engl J Med; 2002 Aug; 347(5):367-8; author reply 367-8. PubMed ID: 12151478 [No Abstract] [Full Text] [Related]
2. GP IIb/IIIa inhibition in primary stenting: 'do it early, make it easy'. Montalescot G Eur Heart J; 2002 Feb; 23(4):259-60. PubMed ID: 11812056 [No Abstract] [Full Text] [Related]
3. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. Stone GW; Grines CL; Cox DA; Garcia E; Tcheng JE; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Carroll JD; Rutherford BD; Lansky AJ; N Engl J Med; 2002 Mar; 346(13):957-66. PubMed ID: 11919304 [TBL] [Abstract][Full Text] [Related]
4. In the era of stabilize and seal, is there a role for GP IIb/IIIa agents in PCI? Gilchrist IC Catheter Cardiovasc Interv; 2010 May; 75(6):903-4. PubMed ID: 20432396 [No Abstract] [Full Text] [Related]
5. Are stenting and glycoprotein IIb/IIIa blockade of good value in primary percutaneous coronary intervention? Cole JH; Weintraub WS Circulation; 2003 Dec; 108(23):2831-3. PubMed ID: 14662689 [No Abstract] [Full Text] [Related]
12. [Impact of GP IIb/IIIa antagonists in interventional cardiology]. Scheller B; Hennen B; Böhm M; Nickenig G Dtsch Med Wochenschr; 2003 Feb; 128(6):281-7. PubMed ID: 12571800 [No Abstract] [Full Text] [Related]
13. [Glycoprotein IIb/IIIa platelet blockers in acute myocardial infarct treated with primary coronary angioplasty]. Kala P; Poloczek M; Bocek O; Jerábek P; Neugebauer P; Kosová J; Semrád B Vnitr Lek; 2002 Aug; 48(8):736-41. PubMed ID: 12425204 [TBL] [Abstract][Full Text] [Related]
14. Platelet glycoprotein IIb/IIIa inhibition as adjunctive therapy during primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Young JJ J Invasive Cardiol; 2005 Jun; 17(6):300-1. PubMed ID: 16003003 [No Abstract] [Full Text] [Related]
15. The safety and efficacy of glycoprotein IIb/IIIa inhibitors for primary angioplasty: more options to choose and more time to decide. Moliterno DJ; Ziada KM J Am Coll Cardiol; 2008 Feb; 51(5):536-7. PubMed ID: 18237681 [No Abstract] [Full Text] [Related]
16. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466 [TBL] [Abstract][Full Text] [Related]
17. Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa inhibition, in acute myocardial infarction. Costantini CO; Stone GW; Mehran R; Aymong E; Grines CL; Cox DA; Stuckey T; Turco M; Gersh BJ; Tcheng JE; Garcia E; Griffin JJ; Guagliumi G; Leon MB; Lansky AJ J Am Coll Cardiol; 2004 Jul; 44(2):305-12. PubMed ID: 15261923 [TBL] [Abstract][Full Text] [Related]